Mixed Readings For Biotech Short Interest

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

DNA
Thinkstock
The short interest data are out for the November 14 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies, such as Ebola-vaccine companies.

The November 14 short interest data has been compared with the October 31 figures, and biotech companies have received mixed readings but for the most part short interest is down.

Amgen Inc. (NASDAQ: AMGN) saw its short interest fall to 9.7 million shares, with 2.51 days to cover. The previous level was 10.8 million. Short interest has retreated from the 52-week high in mid-September of 12.17 million. Despite this, the share price posted an annual high of $165.68 in late November. The stock closed Tuesday at $162.24, and it has a 52-week trading range of $108.20 to $165.68.

Biogen Idec Inc. (NASDAQ: BIIB) saw its short interest drop to 2.48 million, with 2.01 days to cover, from the 2.68 million shares short in late October. Biogen is another company with short interest within a consistent range, specifically 2.0 million to 3.5 million. Shares closed Tuesday at $305.40, and they have a 52-week trading range of $270.27 to $358.89.

Celgene Corp. (NASDAQ: CELG) saw its short interest fall to 12.4 million shares, with 2.76 days to cover. The number of shares short was 13.5 million in late October. The short interest for Celgene can be split into two halves for the year: prior to April short interest held within a range of 4 million to 6 million shares, and since then the range has been 11 million to 15 million. Celgene announced a successful drug trial this quarter for its Crohn’s disease treatment, and the reaction in the market was very positive as the stock seemingly continues to push higher highs. Shares closed Tuesday at $111.07, within a 52-week trading range of $66.85 to $112.82.

Gilead Sciences Inc. (NASDAQ: GILD) short interest increased to 53.92 million shares, with 3.42 days to cover, from the previous level of 51.96 million shares. Despite the recent gains in short interest, the past four readings have been the lowest on the year and they have been part of a declining trend in short interest since late July. The stock closed Tuesday at $101.11 and has a 52-week range of $63.50 to $116.83.

MannKind Corp. (NASDAQ: MNKD) saw its short increase marginally to 82.4 million, with 17.23 days to cover, from the previous 82.02 million shares. The current level is the highest reading for the past 52 weeks, and this trend has been pushing higher, excluding a few drops, for basically the whole year. Investors still appear to be bearish on this stock and have latched on to its most recent slide from its 52-week high in June. MannKind shares closed Tuesday at $6.20, and it has a 52-week trading range of $3.80 to $11.48.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) saw its short interest fall to 2.81 million, with 3.34 days to cover, from 3.21 million in late October. Alexion broke below its normal range for short interest of 3.0 million to 4.5 million shares, giving it the lowest reading on the year. In this period, shares hit a 52-week high. The stock closed Tuesday at $192.77, within a 52-week trading range of $120.14 to $197.64.

ALSO READ: 4 More Biotech Stocks to Buy, With Up to 200% Upside

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618